Everest Medicines Ltd. (HK:1952) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Everest Medicines has announced the approval of its kidney disease drug NEFECON by the Taiwan Food and Drug Administration, marking a significant expansion in its treatment reach for IgA nephropathy, particularly in Asia where the condition is more prevalent. The company also highlighted promising results from a two-year clinical trial in China, showing substantial kidney function protection and reduction in proteinuria among patients. With approvals across several Asian regions, NEFECON is poised to become a leading treatment option for IgAN patients.
For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.